John Richard Pinion Sells 10,029 Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) insider John Richard Pinion sold 10,029 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $228,661.20. Following the completion of the sale, the insider directly owned 110,026 shares in the company, valued at approximately $2,508,592.80. This trade represents a 8.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Ultragenyx Pharmaceutical Stock Down 1.2%

Ultragenyx Pharmaceutical stock opened at $21.80 on Thursday. Ultragenyx Pharmaceutical Inc. has a 52-week low of $18.41 and a 52-week high of $42.37. The firm has a market capitalization of $2.11 billion, a price-to-earnings ratio of -3.73 and a beta of 0.16. The firm has a 50-day moving average price of $23.56 and a two-hundred day moving average price of $29.19.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). The business had revenue of $207.28 million for the quarter, compared to the consensus estimate of $199.60 million. Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The business’s quarterly revenue was up 25.5% on a year-over-year basis. During the same period last year, the firm posted ($1.39) EPS. Research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Institutional Trading of Ultragenyx Pharmaceutical

Large investors have recently added to or reduced their stakes in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 14.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company’s stock valued at $8,414,000 after buying an additional 29,984 shares in the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of Ultragenyx Pharmaceutical by 6.0% during the 2nd quarter. Envestnet Asset Management Inc. now owns 29,956 shares of the biopharmaceutical company’s stock worth $1,089,000 after acquiring an additional 1,698 shares in the last quarter. Teacher Retirement System of Texas grew its holdings in shares of Ultragenyx Pharmaceutical by 1.8% in the 2nd quarter. Teacher Retirement System of Texas now owns 22,773 shares of the biopharmaceutical company’s stock worth $828,000 after acquiring an additional 404 shares during the last quarter. Amalgamated Bank raised its position in shares of Ultragenyx Pharmaceutical by 9.7% during the second quarter. Amalgamated Bank now owns 6,757 shares of the biopharmaceutical company’s stock worth $246,000 after purchasing an additional 598 shares during the period. Finally, EFG Asset Management North America Corp. raised its position in shares of Ultragenyx Pharmaceutical by 10.5% during the second quarter. EFG Asset Management North America Corp. now owns 135,850 shares of the biopharmaceutical company’s stock worth $4,939,000 after purchasing an additional 12,908 shares during the period. 97.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, January 21st. Jefferies Financial Group decreased their target price on shares of Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating for the company in a research report on Tuesday, December 30th. TD Cowen dropped their price target on shares of Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Wells Fargo & Company reduced their price target on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating for the company in a research note on Tuesday, December 30th. Finally, Barclays lowered their price objective on shares of Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating on the stock in a research note on Monday, November 24th. Sixteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Ultragenyx Pharmaceutical presently has an average rating of “Moderate Buy” and a consensus target price of $68.29.

Key Headlines Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Institutional support remains in the register, which can help stabilize the float and provide long‑term demand for shares. Read More.
• Neutral Sentiment: Analyst coverage is still skewed toward buys and the company recently reported revenue beat but an EPS miss (Feb. 12). That mixed fundamental backdrop leaves the stock sensitive to news and revisions.
• Negative Sentiment: Legal overhang: multiple law firms have circulated investor notices and a securities class action has been filed alleging misstatements/omissions related to setrusumab; the lead‑plaintiff deadline (Apr. 6, 2026) concentrates attention on potential damages and litigation risk. Read More.
• Negative Sentiment: Regulatory/program risk amplified: Levi & Korsinsky highlights that RARE plunged ~42% after disclosure of a Phase III failure for setrusumab — that clinical setback remains the root cause of the stock’s heightened volatility and underpins many of the litigation claims. Read More.
• Negative Sentiment: Clustered insider selling: the CEO and several senior executives and officers disclosed large share sales (multiple filings show material blocks around $22.7–22.8), which often weighs on near‑term sentiment and raises questions for some investors. Read More.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.